SIK2 and kidney disorder: In a more recent work, Liu et al. demonstrated that the restoration of the activity of the salt-inducible kinase SIK2 is a promising therapy for diabetic patients with interstitial fibrotic kidney disease, since the underlying molecular mechanisms involve the EP300-dependent SIK2 inactivity in renal tubules of patients and in vivo models using vancomycin-induced kidney disease in murine experiments [54].